Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 07 - 28 source : Www.biospace.com save search
Sanofi Launches HBCU Diversity Partnership, Stays Strong in Q2 as Dupixent Th...
Published: 2022-07-28 (Crawled : 18:00) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.4%
H: 1.01%
C: 0.17%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.68%
H: 0.0%
C: 0.0%
dupixent sanofi
Sanofi Launches HBCU Diversity Partnership, Stays Strong in Q2 as Dupixent Thrives
Published: 2022-07-28 (Crawled : 18:00) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.4%
H: 1.01%
C: 0.17%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.68%
H: 0.0%
C: 0.0%
dupixent sanofi
Kiora Pharmaceuticals Issued US Patent Covering KIO-201 Technology in Combination with Antibiotics
Published: 2022-07-28 (Crawled : 17:00) - biospace.com/
KPRX | $0.601 23.92% 19.3% 1.2M
|
Manufacturing
|
| O: 0.34%
H: 3.38%
C: 0.47%
kio-201 antibiotics patent technology
Sanofi Stays Strong in Q2 as Dupixent thrives. Launches HBCU Diversity Partnership
Published: 2022-07-28 (Crawled : 16:00) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.4%
H: 1.01%
C: 0.17%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.68%
H: 0.0%
C: 0.0%
partnership dupixent sanofi
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDsPrescription Drug User Fee Act (PDUFA) target action date set for January 15, 2023
Published: 2022-07-28 (Crawled : 15:20) - biospace.com/
RLFTF | $1.45 11.45% 1.3K
|
n/a
|
| O: 3.08%
H: 0.0%
C: -6.79%
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 0.7%
H: 4.86%
C: -1.39%
acer-001 treatment fda drug set resubmission therapeutics review
Synlogic Announces Second Quarter 2022 Conference Call and Webcast
Published: 2022-07-28 (Crawled : 15:20) - biospace.com/
SYBX | $1.9 3.26% 3.16% 66K
|
Health Technology
|
| O: 2.91%
H: 0.0%
C: -10.2%
conference
GigaGen Publishes Research Showcasing First-Ever Clinical GMP Manufacturing and IND-Enabling Studies for its New Class of Drugs, Recombinant Polyclonal Antibodies
Published: 2022-07-28 (Crawled : 15:20) - biospace.com/
GRFS | $6.485 2.94% 2.85% 3.4M
|
Health Technology
|
| O: -10.0%
H: 4.69%
C: -0.21%
research
Sanofi Stays Strong in Q2 as Dupixent thrives. Launches HBCU Diversity Partne...
Published: 2022-07-28 (Crawled : 15:20) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.4%
H: 1.01%
C: 0.17%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.68%
H: 0.0%
C: 0.0%
dupixent sanofi
Propanc Biopharma’s CSO Reflects on Unique Anti-Cancer Effects of PRP Discovered Over Past Decade
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
PPCB | $0.0011 -41.86% 5.6M
|
Manufacturing
|
| O: 2.38%
H: 0.0%
C: -18.6%
unique cancer
BIO-TECHNE ANNOUNCES LICENSING AGREEMENT AND PARTNERSHIP WITH UNIVERSITY OF DUNDEE
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
TECH | $63.675 1.39% 1.37% 1.2M
|
Health Technology
|
| O: 0.57%
H: 2.03%
C: 1.12%
partnership agreement
Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
GLAXF | News | $20.305 -14.18% 630
|
Health Technology
|
| O: -1.01%
H: 0.0%
C: -2.13%
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
|
| O: -1.54%
H: 0.91%
C: 0.14%
sdc-1801 application trial update
ViiV Healthcare Announces New Data at AIDS 2022 From Unblinded Phase of HPTN 084 Study in Women in Sub-Saharan Africa Showing Continued Superior Efficacy of Injectable Cabotegravir Long-Acting for PrEP Over Daily, Oral TDF/FTC Tablets
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: -2.13%
H: 2.92%
C: -0.25%
women study africa
ViiV Healthcare and the Medicines Patent Pool Sign New Voluntary Licensing Agreement to Expand Access to Innovative Long-Acting HIV Prevention Medicine
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: -2.13%
H: 2.92%
C: -0.25%
patent hiv agreement
Tonix Pharmaceuticals Announces Collaboration with Kenya Medical Research Institute to Develop TNX-801 in Kenya as a Vaccine for the Prevention of Monkeypox and Smallpox Infection
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
TNXP | $0.1574 1.29% 1.27% 1.6M
|
Health Technology
|
| O: 5.62%
H: 11.83%
C: 10.65%
tnx-801 monkeypox smallpox research collaboration vaccine infection
Sientra to Report Second Quarter 2022 Financial Results on August 11, 2022
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
SIEN | $0.174 0.69% 3.4M
|
Health Technology
|
| O: 0.54%
H: 5.46%
C: 1.46%
report results
Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate)
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
CRXT | $0.0475
|
|
| O: 4.29%
H: 1.99%
C: -3.73%
jatenzo patent therapeutics
The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: -0.26%
H: 1.35%
C: 0.87%
biib059 lupus positive phase 2
Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
AGNPF | $0.0716 178.69% 12K
|
Health Technology
|
| O: 0.12%
H: 1.62%
C: 1.62%
positive study phase 2
FDA Clears DyAnsys Neurostimulation Device Primary Relief to Treat C-Section Pain
Published: 2022-07-28 (Crawled : 14:20) - biospace.com/
ANSS | $325.63 0.25% 0.25% 180K
|
Technology Services
|
| O: -0.26%
H: 4.84%
C: 4.52%
fda device
Tallac Therapeutics Announces First Patient Dosed with TAC-001, a First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugate, in a Phase 1/2 Study for Patients with Advanced Solid Tumors
Published: 2022-07-28 (Crawled : 14:20) - biospace.com/
ALXO M | $15.5 8.92% 8.19% 440K
|
Commercial Services
|
| O: -0.33%
H: 0.25%
C: -7.46%
tac-001 antibody therapeutics study
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.